Treating anomia in semantic dementia: improvement, maintenance, or both?
Regina Jokel1, Elizabeth Rochon, Carol Leonard
1Graduate Department of Speech-Language Pathology, University of Toronto, Baycrest Centre for Geriatric Care, Toronto, Ontario, Canada.
Neuropsychological Rehabilitation
|July 13, 2006
Summary
This study describes a home-based treatment for anomia in semantic dementia, showing that practice helped patients relearn object names and slowed word loss progression.
Area of Science:
- Neurology
- Psycholinguistics
- Cognitive Rehabilitation
Background:
- Semantic dementia is a neurodegenerative condition characterized by progressive loss of semantic knowledge, often leading to anomia (word-finding difficulties).
- Anomia, a core symptom, significantly impacts daily communication and quality of life for affected individuals.
Observation:
- A specific treatment program was designed for a patient (AK) with anomia resulting from semantic dementia.
- The program emphasized home-based practice, involving the patient in decision-making for treatment design.
Findings:
- The treatment facilitated the relearning of object names that the patient could not previously name or comprehend.
- Positive treatment effects, particularly for items the patient could comprehend but not name, persisted one month post-intervention.
- Practice demonstrated a beneficial effect on word retention, delaying the progression of lexical retrieval deficits.
Implications:
- Home-based, patient-centered interventions can be effective in managing anomia in semantic dementia.
- Targeted practice may not only aid in relearning lost words but also help preserve existing lexical knowledge.
- Findings suggest potential strategies for improving functional communication and slowing cognitive decline in neurodegenerative language disorders.
Related Concept Videos
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:13Amnesia
Amnesia is a condition marked by long-term memory loss, which impairs the ability to recall past events or create new memories.
The severity and duration of memory loss vary depending on the type and underlying cause. Amnesia is classified into two main types: retrograde and anterograde.
Retrograde amnesia is marked by the loss of memories formed before the onset of the condition. Patients may recall distant past events but often forget those occurring shortly before the incident.
Anterograde...
The severity and duration of memory loss vary depending on the type and underlying cause. Amnesia is classified into two main types: retrograde and anterograde.
Retrograde amnesia is marked by the loss of memories formed before the onset of the condition. Patients may recall distant past events but often forget those occurring shortly before the incident.
Anterograde...
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:35Long-term Potentiation
Long-term potentiation, or LTP, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTP is the process of synaptic strengthening that occurs over time between pre- and postsynaptic neuronal connections. The synaptic strengthening of LTP works in opposition to the synaptic weakening of long-term depression (LTD) and together are the main mechanisms that underlie learning and memory.